US12186307B2ActiveUtilityA1

Methods of treating epilepsy

49
Assignee: UNIV YALEPriority: Feb 13, 2019Filed: Feb 13, 2020Granted: Jan 7, 2025
Est. expiryFeb 13, 2039(~12.6 yrs left)· nominal 20-yr term from priority
Inventors:Angelique BordeyLongbo Zhang
A61K 31/192G01N 2800/50G01N 2800/2821G01N 2333/70571G01N 2333/4712G01N 33/6896A61P 25/08A61P 25/28A61K 31/4747A61P 25/18A61K 31/438A61K 31/196
49
PatentIndex Score
0
Cited by
25
References
5
Claims

Abstract

In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator. In various embodiments, the FLNA modulator is PTI-125 or kartogenin. In various embodiments, the epilepsy is epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC).

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
       1. A method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator, wherein the epilepsy is intractable epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC). 
     
     
       2. The method according to  claim 1 , wherein the FLNA modulator is PTI-125. 
     
     
       3. The method according to  claim 1 , wherein the FLNA modulator is formulated in a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient. 
     
     
       4. The method according to  claim 1 , wherein the subject is a mammal. 
     
     
       5. The method according to  claim 1 , wherein the subject is a human.

Join the waitlist — get patent alerts

Track US12186307B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.